HomeCompareESAIY vs O

ESAIY vs O: Dividend Comparison 2026

ESAIY yields 3.13% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 O wins by $9.7K in total portfolio value· pulled ahead in Year 5
10 years
ESAIY
ESAIY
● Live price
3.13%
Share price
$7.66
Annual div
$0.24
5Y div CAGR
0.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.6K
Annual income
$400.49
Full ESAIY calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — ESAIY vs O

📍 O pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESAIYO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESAIY + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESAIY pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESAIY
Annual income on $10K today (after 15% tax)
$266.34/yr
After 10yr DRIP, annual income (after tax)
$340.42/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, O beats the other by $3,996.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESAIY + O for your $10,000?

ESAIY: 50%O: 50%
100% O50/50100% ESAIY
Portfolio after 10yr
$29.4K
Annual income
$2,751.62/yr
Blended yield
9.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

ESAIY
No analyst data
Altman Z
3.0
Piotroski
7/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESAIY buys
0
O buys
0
No recent congressional trades found for ESAIY or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESAIYO
Forward yield3.13%5.28%
Annual dividend / share$0.24$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.4%15.1%
Portfolio after 10y$24.6K$34.2K
Annual income after 10y$400.49$5,102.74
Total dividends collected$3.6K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: ESAIY vs O ($10,000, DRIP)

YearESAIY PortfolioESAIY Income/yrO PortfolioO Income/yrGap
1$11,015$314.60$10,818$608.16+$197.00ESAIY
2$12,111$325.14$11,787$741.68+$324.00ESAIY
3$13,294$335.45$12,946$911.00+$348.00ESAIY
4$14,570$345.51$14,345$1,127.94+$225.00ESAIY
5← crossover$15,945$355.31$16,056$1,409.05$111.00O
6$17,426$364.87$18,171$1,777.83$745.00O
7$19,020$374.16$20,820$2,268.21$1.8KO
8$20,735$383.19$24,188$2,929.90$3.5KO
9$22,578$391.97$28,533$3,837.11$6.0KO
10$24,559$400.49$34,235$5,102.74$9.7KO

ESAIY vs O: Complete Analysis 2026

ESAIYStock

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESAIY Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ESAIY vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESAIY vs SCHDESAIY vs JEPIESAIY vs KOESAIY vs MAINESAIY vs STAGESAIY vs ADCESAIY vs NNNESAIY vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.